Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops medicines to bring the curative power of stem cell transplants to patients with blood cancers, genetic diseases, and autoimmune diseases. It develops MGTA-117, an anti-CD117 antibody that targets hematopoietic stem cells (HSCs) and genetically mutated stem cells that cause acute myeloid leukemia and myelodysplastic syndromes, which is under Phase I/II clinical trial; CD45-antibody drug conjugate that targets HSCs and immune cells, which is in investigational new drug application enabling studies for potential use as a single-agent in autoimmune diseases and hematology-oncology transplants; and MGTA-145 that is in Phase II clinical trial for use in autologous and allogeneic transplants. The company also has a cell therapy program, E478, which is a small molecule aryl hydrocarbon receptor antagonist for stem cell-based gene therapy and genome editing. Magenta Therapeutics, Inc. has a research and clinical collaboration agreement with AVROBIO, Inc. for the treatment of lysosomal storage disorders; and Beam Therapeutics, Inc. to evaluate the potential utility of MGTA-117 for conditioning of patients with sickle cell disease and beta-thalassemia. The company was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. Magenta Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Magenta Therapeutics, Inc.

Magenta Therapeutics is a clinical-stage biotechnology company developing medicines to bring the curative power of stem cell transplant to more patients with blood cancers, genetic diseases and autoimmune diseases. Magenta is combining leadership in stem cell biology and biotherapeutics development with clinical and regulatory expertise, a unique business model and broad networks in the stem cell transplant community to revolutionize immune reset for more patients.Magenta is based in Cambridge, Mass. For more information, please visit www.magentatx.com.Follow Magenta on Twitter: @magentatx.

	Dec '16	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22
revenue
cost of revenue
gross profit
selling and marketing expenses
general and administrative expenses	3.49M -	7.83M 124.56%	18.62M 137.90%	23.76M 27.59%	28.09M 18.21%	27.93M 0.57%	25.76M 7.75%
selling general and administrative expenses	3.49M -	7.83M 124.56%	18.62M 137.90%	23.76M 27.59%	28.09M 18.21%	27.93M 0.57%	25.76M 7.75%
research and development expenses	5.78M -	27.90M 382.51%	41.34M 48.18%	59.21M 43.22%	50.62M 14.51%	46.77M 7.60%	55.14M 17.91%
other expenses
cost and expenses	9.27M -	35.73M 285.49%	59.96M 67.84%	82.97M 38.37%	78.70M 5.14%	74.69M 5.10%	80.90M 8.31%
operating expenses	9.27M -	35.73M 285.49%	59.96M 67.84%	82.97M 38.37%	78.70M 5.14%	74.69M 5.10%	80.90M 8.31%
interest expense	163K -						-4.44M -
ebitda	-9.26M -	-35.12M 279.13%	-59.96M 70.76%	-82.97M 38.37%	-78.70M 5.14%	-74.69M 5.10%	-78.98M 5.74%
operating income	-9.27M -	-35.73M 285.49%	-59.96M 67.84%	-82.97M 38.37%	-78.70M 5.14%	-74.69M 5.10%	-80.90M 8.31%
depreciation and amortization	6K -	376K 6,166.67%	875K 132.71%	1.84M 110.63%	1.98M 7.33%	2.02M 2.12%	1.93M 4.70%
total other income expenses net	-163K -	236K 244.79%	2.45M 937.29%	6.20M 153.27%	3.77M 39.26%	3.56M 5.58%	4.44M 24.86%
income before tax	-9.43M -	-35.49M 276.32%	-57.52M 62.06%	-76.77M 33.48%	-74.94M 2.39%	-71.14M 5.07%	-76.46M 7.49%
income tax expense		236K -	2.45M 937.29%	-8.04M 428.55%	-5.74M 28.58%	-5.58M 2.92%	-4.44M 20.37%
net income	-9.43M -	-35.49M 276.32%	-57.52M 62.06%	-68.73M 19.49%	-69.19M 0.68%	-65.56M 5.25%	-72.02M 9.86%
weighted average shs out	21.50M -	21.50M 0%	18.39M 14.46%	37.01M 101.28%	43.92M 18.66%	54.95M 25.11%	59.37M 8.05%
weighted average shs out dil	21.50M -	21.50M 0%	18.39M 14.46%	37.01M 101.28%	43.92M 18.66%	54.95M 25.11%	59.37M 8.05%
eps	-0.44 -	-1.65 275%	-3.13 89.70%	-1.86 40.58%	-1.58 15.05%	-1.19 24.68%	-1.21 1.68%
epsdiluted	-0.44 -	-1.65 275%	-3.13 89.70%	-1.86 40.58%	-1.58 15.05%	-1.19 24.68%	-1.21 1.68%

COM:MAGENTATX

Dianthus Therapeutics, Inc.

Last Close

0.76

11/09 20:00

Market Cap

42.44M

Beta: -

Volume Today

375.91K

Avg: -

Preview